Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR−proficient non−metastatic rectal cancer: a meta-analysis of randomized controlled trials
AimIn proficient mismatch repair (pMMR) non metastatic rectal cancer, standard neoadjuvant chemoradiotherapy (nCRT) yields low pathological and clinical complete response rates. Early randomized trials suggest adding PD 1 inhibitors may increase response but randomized evidence has not been synthesi...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2026-03-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1792283/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|